Study2016Open access

Docosahexaenoic acid liposomes for targeting chronic inflammatory diseases and cancer: an in vitro assessment

Alaarg A, Jordan NY, Verhoef JJ, Metselaar JM, Storm G, Kok RJ

International journal of nanomedicine · 37 citations

Review labels

Funding not disclosedMechanisms only

Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.

How it was studied

Design
In vitro/mechanistic study (classified by our AI screen)
Studied in
People, plus animal or lab work
Main outcome
Mechanisms only

Who paid for it

Funding
Funding not disclosed

Publication

Published
2016-10-01 · Int J Nanomedicine · vol. Volume 11 · pp. 5027–5040
Publisher
Dove Medical Press
Cited
59 citations · more than 95% of similar papers · 4.7× the field average
Impact
Top 10% most cited in its field
References
48 works
Access
Open access (journal) · CC-BY-NC
Research areas
Fatty Acid Research and Health · Cholesterol and Lipid Metabolism · Eicosanoids and Hypertension Pharmacology
Keywords
Docosahexaenoic acid, Fish oil, Proinflammatory cytokine, Polyunsaturated fatty acid, Inflammation, Liposome, Immune system, Eicosapentaenoic acid, Cancer, Cancer cell, Cancer research, Pharmacology, Reactive oxygen species, Chemistry, Immunology, Medicine, Biology, Biochemistry, Fatty acid, Internal medicine
MeSH
monocytes, cells, cultured, macrophages, animals, humans, mice, carcinoma, squamous cell, breast neoplasms, inflammation, reactive nitrogen species, reactive oxygen species, docosahexaenoic acids, tumor necrosis factor-alpha, cytokines, liposomes, cell proliferation, oxidative stress, female, human umbilical vein endothelial cells, in vitro techniques

6 authors

From NL, DE

  • Amr AlaargUtrecht University; University of Twente
  • Nan Yeun JordanUtrecht University; Pharmo Institute; University of Twente
  • Johan J. F. VerhoefUtrecht University; Pharmo Institute
  • Josbert M. MetselaarUtrecht University; Pharmo Institute; RWTH Aachen University; University of Twente
  • Gert StormUtrecht University; Pharmo Institute; University of Twente
  • Robbert J. KokUtrecht University; Pharmo Institute

Abstract

Inflammation, oxidative stress, and uncontrolled cell proliferation are common key features of chronic inflammatory diseases, such as atherosclerosis and cancer. ω3 polyunsaturated fatty acids (PUFAs; also known as omega3 fatty acids or fish oil) have beneficial effects against inflammation upon dietary consumption. However, these effects cannot be fully exploited unless diets are enriched with high concentrations of fish oil supplements over long periods of time. Here, a nanomedicine-based approach is presented for delivering effective levels of PUFAs to inflammatory cells. Nanoparticles are internalized by immune cells, and hence can adequately deliver bioactive lipids into these target cells. The ω3 FA docosahexaenoic acid was formulated into liposomes (ω-liposomes), and evaluated for anti-inflammatory effects in different types of immune cells. ω-Liposomes strongly inhibited the release of reactive oxygen species and reactive nitrogen species from human neutrophils and murine macrophages, and also inhibited the production of the proinflammatory cytokines TNFα and MCP1. Moreover, ω-liposomes inhibited tumor-cell proliferation when evaluated in FaDu head and neck squamous carcinoma and 4T1 breast cancer cells in in vitro cultures. We propose that ω-liposomes are a promising nanonutraceutical formulation for intravenous delivery of fish oil FAs, which may be beneficial in the treatment of inflammatory disorders and cancer.

Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY-NC).

Community trust

Loading…

How much do you trust this study's findings?

0 · not at all10 · completely

Comments

Sign in to rate, comment on or flag this study.Sign in

Something wrong here?

Flag this study if its information, labels or funding look wrong. An editor reviews every flag.

Sign in to rate, comment on or flag this study.Sign in

Educational information about published research. Not medical advice, and not a recommendation to start or stop anything.